INNPF
INNOCAN PHARMA Corp·Healthcare
2.60
2.622%(−0.07)
Close PriceLast Updated: — ET
52W L: $2.6052W H: $14.26
INNPF NEWS
prnewswire.com
9h ago
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on
prnewswire.com
Mar 31
Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete
prnewswire.com
Mar 31
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended December 31, 2025. Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.
prnewswire.com
Feb 27
FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the third consecutive year. The FDA's Center for Veterinary Medicine (CVM) assesses annual fees for animal drug applications.
